LM-10

• CAT Number: I000006
• CAS Number: 1316695-35-8
• Molecular Formula: C11H8FN5
• Molecular Weight: 229.21
• Purity: ≥95%
• Synonyms: LM 10
• Target: Tryptophan 2,3-dioxygenase Inhibitor
• Solubility: Soluble to 100 mM in DMSO and to 20 mM in ethanol with gentle warming
• Storage: Store at -20°C
• IC50: 0.62 and 2 μM for human and mouse TDO
• InChI: InChI=1S/C11H8FN5/c12-8-2-3-9-7(6-13-10(9)5-8)1-4-11-14-16-17-15-11/h1-6,13H,(H,14,15,16,17)/b4-1+
• InChIKey: JDBSZVDIUIRSDG-DAFODLJHSA-N
• SMILES: FC1=CC2=C(C=C1)C(/C=C/C3=NN=NN3)=CN2

LM-10 (CAT: I000006) is a selective inhibitor of tryptophan 2,3-dioxygenase (TDO). TDO is an enzyme involved in the kynurenine pathway, which metabolizes tryptophan. By inhibiting TDO, LM-10 can modulate tryptophan metabolism and potentially have effects on immune responses and neurological functions. It may have applications in the field of immunology, neurology, and cancer research.

Reference

1:Exp Neurol. 1996 Sep;141(1):47-56. The hematopoietic cytokine colony stimulating factor 1 is also a growth factor in the CNS: (II). Microencapsulated CSF-1 and LM-10 cells as delivery systems.Maysinger D,Berezovskaya O,Fedoroff S, PMID: 8797667 DOI: 10.1006/exnr.1996.0138 Abstract: The aim of this study was to develop delivery systems for administration of CSF-1 to remedy the systemic deficiency of this cytokine in osteopetrotic op/op mice and to study the microglial response and neuronal survival in op/op mice following cerebral cortex ischemic lesion. Unilateral cerebral cortex ischemic lesions were produced in homozygous op/op mice and either microencapsulated rhCSF-1 or LM-10 fibroblast-like cells producing CSF-1 were administered either locally, at the site and time of the lesioning, or into the peritoneum 2 weeks before the lesion was made. Physical properties (shape, size, integrity) and kinetics of rhCSF-1 release were assessed prior to the experiments in situ. Depending on the characteristics of the biodegradable polymer (e.g., chitosan with different densities or poly-L-lactic-poly-glycolic acid), remarkable differences in survival of encapsulated cells were observed. Cellular integrity following encapsulation and metabolic activity was regularly assessed for a period of 1 month. The best level of viability was achieved with highly viscous chitosan (311). The results from these studies demonstrate that: (1) rhCSF-1 incorporated into biodegradable spheres can be released and retain its biological activity; (2) microencapsulated LM-10 cells which produce CSF-1 can survive and constitutively release CSF-1 in alginate-chitosan spheres for different lengths of time depending on the physical properties of the chitosan used; and (3) CSF-1 is an important growth factor in the central nervous system where it can both strongly alter morphological changes of microglia and enhance survival of neurons in injured brain.